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Abstract
Introduction: The objective of this study was to investigate the effects of tumor necrosis factor (TNF)-a inhibitors
on circulating T helper-type 17 (Th17) cells and Th17-related cytokines in patients with rheumatoid arthritis (RA).
Methods: The frequencies of circulating Th17 cells and serum levels of Th17-related cytokines were determined
using flow cytometry analysis and ELISA, respectively, in 48 RA patients both before (baseline) and six months after
anti-TNF-a therapy. Therapeutic response was evaluated using European League Against Rheumatism (EULAR)
response criteria.
Results: Significantly higher baseline frequencies of circulating Th17 cells and serum levels of interleukin (IL)-6, IL-
17, IL-21, IL-23 and TNF-a were observed in active RA patients than in 12 healthy controls (all P < 0.001). After anti-
TNF-a therapy, 36 patients (75%) were EULAR responders (20 good responders and 16 moderate responders) and
12 (25.0%) were non-responders. The mean levels of circulating Th17 cells and IL-17 significantly decreased (1.13%
vs. 0.79%; 43.1 pg/ml vs. 27.8 pg/ml; respectively, both P < 0.001) in parallel with clinical remission in responders.
Levels of IL-6, IL-21, IL-23 and TNF-a were significantly decreased after anti-TNF-a therapy in responders. In
contrast, the mean levels of circulating Th17 cells and IL-17 significantly increased after anti-TNF-a therapy (2.94%
vs. 4.23%; 92.1 pg/ml vs. 148.6 pg/ml; respectively, both P < 0.05) in non-responders. Logistic regression analysis
identified a high baseline level of IL-17 as a significant predictor of poor therapeutic response.
Conclusions: The beneficial effect of anti-TNF-a therapy might involve a decrease in Th17-related cytokines in
responders, whereas rising levels of circulating Th17-cells and IL-17 were observed in patients with an inadequate
response to anti-TNF-a therapy.
Introduction
Rheumatoid arthritis (RA) is characterized by the infil-
tration of macrophages and T cells into the joints, syno-
vial hyperplasia, cartilage degradation and bone erosions
[1]. Tumor necrosis factor (TNF)-a is a crucial inflam-
matory mediator in rheumatoid synovitis and subse-
quent tissue damage in RA [2,3]. Although TNF-a
inhibitors can be an effective and well-tolerated therapy
for RA patients [4-6], a significant proportion of patients
do not acquire advantageous effects [7]. In addition, the
effect of TNF-a inhibitors on the immune response has
not been fully explored.
T helper-type 17 (Th17) cells, a novel and distinct
subset of Th cell, can secrete interleukin (IL)-17 in
humans [8-10]. Interleukin-17 is a pleiotropic cytokine
that participates in tissue inflammation and destruction
by inducing the expression of pro-inflammatory cyto-
kines and matrix metalloproteases [8,11,12]. The fre-
quencies of Th17 cells were found to increase in
peripheral blood mononuclear cells (PBMCs) of RA
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enhanced expression of IL-17 has been observed in the
rheumatoid synovium [15] and synovial fluids of patients
with early RA [16]. Interleukin-17 in vitro stimulates the
production of TNF-a and IL-1b, and also synergizes
with TNF-a to induce cartilage loss and promote osteo-
clastogenesis [17,18]. A recent study showed that Th17
cells, but not Th1 cells, cooperate with synovial fibro-
blasts in a pro-inflammatory feedback loop that drives
chronic destruction in RA [19]. Moreover, IL-17 has
become a new therapeutic target for animal models with
collagen-induced arthritis (CIA) and human RA [20-22].
These observations suggest that Th17 cells and IL-17
critically contribute to synovitis and bone destruction
associated with RA.
Recently, TNF-a was shown in vitro to drive the pro-
duction of IL-17 with the ability to differentiate T cells
towards a Th17 phenotype [23]. In a psoriasis-like skin
inflammation model, TNF-a enhanced the expression of
Th17-related cytokine genes during priming but sup-
pressed these cytokine transcripts when present during
re-stimulation [24]. In CIA, TNF-a inhibitors reduced
the number of Th17 cells in pathologic joints despite an
increase of Th17 cells in inguinal lymph nodes [25].
Taken together, these findings show that TNF-a block-
ade has paradoxical effects on the expression of Th17-
related cytokines in animal models of autoimmune
diseases.
In humans, an engineered p75 TNFRII dimer, etaner-
cept, suppressed the gene expression levels of Th17-
related cytokines including IL-6 and IL-23 in cutaneous
lesions of psoriasis [26]. Kageyama et al. also reported a
significant decrease in serum levels of IL-23 at three
and six months after etanercept therapy in RA patients
[27]. TNF-a inhibitor, adalmumab, reduced the fre-
quency of circulating Th17 cells and serum IL-6 levels
in RA patients [28]. However, a recent study showed
that an increased frequency of circulating Th17 cells
after TNF-a blockade is accompanied by a decrease in
Th17-specific chemokine receptor expression in RA
[29]. When taken together, these results reveal conflict-
ing effects of TNF-a inhibitors on Th17 cells and IL-17
in humans.
In the present study, we attempted to determine
whether or not the clinical response to anti-TNF-a ther-
apy of RA patients led to changes in the levels of circu-
lating Th17 cells and Th17-related cytokines, and we
also investigated their clinical implication.
Materials and methods
Patients
A total of 48 consecutive patients (39 females and 9
males; mean age ± SD 50.1 ± 13.5 years), who fulfilled
the 1987 revised criteria of the American College of
Rheumatology for RA [30], were evaluated before and
six months after anti-TNF-a therapy. All patients
remained in active disease in spite of treatment with
methotrexate (MTX) and other disease-modifying anti-
rheumatic drugs (DMARDs), for whom anti-TNF-a
therapy was initiated based on the British Society for
Rheumatology guidelines [31]. Fourteen patients
received etanercept at a dose of 25 mg twice weekly and
34 patients received adalimumab at a dose of 40 mg
every other week in combination with a stable dose of
MTX of 7.5 to 15 mg weekly. Corticosteroids (≦10 mg/
day) and non-steroid anti-inflammatory drugs (NSAIDs)
w e r ea l l o w e db u tw e r eg i v e na ts t a b l ed o s e sf o ra tl e a s t
four weeks before and during the six-month anti-TNF-a
therapy. Disease activity was assessed by the 28-joint
disease activity score (DAS28) [32]. The therapeutic
response was evaluated six months after anti-TNF-a
therapy was started, according to the European League
Against Rheumatism (EULAR) response criteria [33].
The patients were categorized into good, moderate or
non-responders based on the amount of change in the
DAS28 and the level of DAS28 reached. Good respon-
ders are defined as patients who have a decrease in
DAS28 from baseline (ΔDAS28) of >1.2 and a DAS28 at
the sixth month of < 3.2; moderate responders have
either ΔDAS28 of >1.2 and a DAS28 at the sixth month
of ≧3.2 or ΔDAS28 of 0.6 to 1.2 and a DAS28 at the
sixth month of < 5.1; and non-responders are those who
have either ΔD A S 2 8o f<0 . 6o raD A S 2 8a tt h es i x t h
month of ≧5.1 [33]. To obtain a better analysis, we com-
bined good responders and moderate responders into
EULAR responders. Twelve age- and sex-matched
healthy volunteers (10 females and 2 males, 47.6 ± 8.1
years), who had no rheumatic disease, were used as nor-
mal controls. Blood samples were collected at baseline
(before starting anti-TNF-a therapy) and six months
after anti-TNF-a therapy. The Ethics Committee of Tai-
chung Veterans General Hospital approved this study
and the written consent of each participant was
obtained.
Quantitation of circulating Th17cells using flow cytometry
analysis
In order to detect circulating Th17 cells, phycoerythrin
(PE)-conjugated anti-IL-17 (eBioscience, San Diego, CA,
USA) and Phycoerythrin-Cyanin 5 (PC5)-conjugated
anti-CD4 (Beckman Coulter, Marseilles, France) were
quantified using flow cytometry according to the manu-
facturer’s protocol and a technique previously described
[34,35]. Briefly, aliquots of 1,000 μl of the sterile hepari-
nized whole blood were stimulated with a combination
of 25 ng/ml of phorbol myristate acetate and 1 μg/ml of
ionomycin (Sigma, Deisenhofen, Germany) and cultured
for one hour at 37°C in a humidified 5% CO2 incubator.
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(Sigma, Germany) to inhibit intracellular protein trans-
port. Activated cultures of blood samples were washed
in wash buffer (phosphate buffered saline, 5% foetal
bovine serum, 0.1% sodium azide; Merck, Darmstadt,
Germany) and then stained with 20 μlo fP C 5 - c o n j u -
gated CD4-specific monoclonal antibody (mAb) (Beck-
man Coulter, Marseilles, France) for 15 minutes at room
temperature (RT). Erythrocytes were lysed by adding 2
ml of fluorescence-activated cell sorter (FACS) lysing
solution (Becton Dickinson, Lincoln Park, NJ, USA).
After five minutes of incubation, the samples were cen-
trifuged and washed with 0.1% BSA-PBS, and subse-
quently fixed with 100 μl Reagent 1 (Beckman Coulter,
Marseilles, France) for 10 minutes. After washing, the
pellet was incubated with 100 μl Reagent 2, saponin
(Beckman Coulter, Marseilles, France) for five minutes
at RT in the dark. The samples were washed twice with
0.1% BSA-PBS and then incubated with PE-conjugated
IL-17-specific mAb (eBiosciences, San Diego, CA, USA)
for 30 minutes at RT in the dark. An isotype control
IgG1-PE (eBiosciences, USA) was used for the IL-17
staining at RT in the dark. After staining, the cells were
washed and immediately analysed using flow cytometry
(Beckman Coulter, USA). Lymphocytes were gated on
the basis of forward- and side- scatter properties and at
least 10,000 CD4
+ cells were analysed. The results were
analysed using Expo32 software (Beckman Coulter,
Miami, FL, USA).
Determination of serum levels of Th17-related cytokines
by ELISA
Serum levels of IL-6, IL-17, IL-21, IL-23 and TNF-a
were determined in 48 RA patients at baseline and after
six months of anti-TNF-a therapy, and in 12 healthy
controls using enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions
(eBiosciences, USA).
Determination of serum levels of anti-cyclic citrullinated
peptide (anti-CCP) antibody and rheumatoid factor (RF)-
IgM
Determination of the anti-CCP antibody was performed
by ELISA using a commercial kit (INOVA Diagnostics
Inc., San Diego, CA, USA). A result was considered
positive for anti-CCP antibodies if the titer was above
20 IU/ml. Serum levels of RF-IgM were measured by
nephelometry (Dade Behring Inc., Newark, DE, USA). A
result was considered positive for RF when the concen-
tration was above 15 IU/ml.
Statistical analysis
The results are presented as the mean ± SD or median
(interquartile range, IQR). The non-parametric Mann-
Whitney U test was used for between-group compari-
sons of serum levels of IL-6, IL-17, IL-21, IL-23 and
TNF-a, and for the percentages of circulating Th17
cells. The correlation coefficient was obtained by the
non-parametric Spearman’s rank correlation test. The
Wilcoxon signed rank test was used to compare the per-
centages of circulating Th17 cells and serum levels of
Th17-related cytokines during follow-up for the RA
patients after anti-TNF-a therapy. A probability of less
than 0.05 was considered significant.
Results
Baseline characteristics of RA patients with a different
therapeutic response
As illustrated in Table 1, the majority of RA patients
were female and all patients had active disease (DAS28,
mean ± SD, 7.22 ± 0.79) before starting anti-TNF-a
therapy. After anti-TNF-a therapy, 36 (75.0%) patients
were EULAR responders, including 20 (41.7%) good
responders and 16 (33.3%) moderate responders,
whereas 12 (25.0%) were non-responders. Although
non-responders had higher erythrocyte sedimentation
rates (ESR) and RF titers compared to responders, the
differences did not reach statistical significance. There
were also no significant differences in the baseline
demographic data, positive rate of RF and anti-CCP
antibodies, daily dose of corticosteroids, or the propor-
tion of patients previously using DMARDs between
responders and non-responders.
The frequencies of circulating Th17 cells in RA patients
before anti-TNF-a therapy
Representative examples of flow cytometric dot-plots of
intracellular IL-17 staining in Th cells obtained from the
PB of one RA patient and from a healthy control are
shown in Figure 1 A. Significantly higher baseline fre-
quencies of circulating Th17 cells were observed in RA
patients (median 1.11%, IQR 0.50% to 2.05%) than in
healthy controls (median 0.12%, IQR 0.05% to 0.18%; P
<0 . 0 0 1 ,F i g u r e1 B ) .A m o n gt h eR Ap a t i e n t s ,s i g n i f i -
cantly higher baseline frequencies of circulating Th17
cells were observed in EULAR non-responders than in
responders (P < 0.01, Figure 2A).
Serum levels of Th17-related cytokines in RA patients
before anti-TNF-a therapy
As shown in Figure 1, the baseline serum levels of
Th17-related cytokines including IL-17, IL-6, IL-21 and
IL-23, were significantly higher in RA patients than in
healthy controls. Among the RA patients, significantly
higher IL-17 levels were observed in non-responders
than in responders (P <0 . 0 1 ,F i g u r e2a n dT a b l e2 ) .
Although non-responders seemed to have higher levels
of IL-6 and TNF-a when compared to the levels in
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nificance. There was also no significant difference in the
levels of Th17-related cytokines between the etanercept-
treated group and the adalimumab-treated group (data
not shown).
Correlation between the frequencies of circulating Th17
cells and disease activity or serum levels of Th17-related
cytokines in RA patients
The frequencies of circulating Th17 cells were positively
correlated with DAS28 scores (r = 0.294, P <0 . 0 5 ) ,I L -
17 levels (r = 0.737, P < 0.001), IL-6 levels (r = 0.347, P
< 0.05), and TNF-a levels (r = 0.495, P < 0.001) in RA
patients before the anti-TNF-a therapy was started.
Serum IL-6 levels were also positively correlated with
IL-17 levels (r = 0.303, P < 0.05) in RA patients. After
six months of anti-TNF-a therapy, the frequencies of
circulating Th17 cells remained positively correlated
with DAS28 scores (r = 0.375, P < 0.01), IL-17 levels (r
= 0.727, P < 0.001), IL-6 levels (r = 0.311, P < 0.05), and
TNF-a levels (r = 0.362, P < 0.05).
Effects of TNF-a inhibitors on the levels of Th17 cells and
Th17-related cytokines
As illustrated in Figure 2 and Table 2, the mean levels
of circulating Th17 cells and IL-17 significantly declined
after six-month anti-TNF-a therapy (1.13% vs. 0.79%;
43.1 pg/ml vs. 27.8 pg/ml; respectively, both P <0 . 0 0 1 ) ,
in parallel with the decrease in DAS28 (7.18 vs. 5.21, P
< 0.001) and in anti-CCP titers (58.7 ± 9.6 vs. 51.8 ± 8.7
IU/ml, P < 0.005) in responders. Serum levels of IL-6,
IL-21, IL-23 and TNF-a were also significantly
decreased after anti-TNF-a therapy in responders. In
contrast, the mean levels of circulating Th17 cells and
IL-17 significantly increased (2.94% vs. 4.23%; 92.1 pg/
ml vs. 148.6 pg/ml; respectively, both P <0 . 0 5 ) ,w h i l e
TNF-a levels decreased after anti-TNF-a therapy (29.2
pg/ml vs. 15.2 pg/ml, P < 0.005) in non-responders.
There were no significant changes in RF titers after
anti-TNF-a therapy in either responders or non-
responders.
Multiple logistic regression analysis of the effects of Th17
cell frequencies and serum Th17-related cytokines on
therapeutic efficacy
Multiple logistic regression analysis showed that only a
high baseline IL-17 level (≧40.0 pg/ml) could signifi-
cantly predict a poor response to anti-TNF-a therapy (P
< 0.01), with a medium level of specificity (83.3%) and
sensitivity (66.7%).
Discussion
Consistent with the findings of previous reports [36,37],
our results showed that 36 (75.0%) patients have moder-
ate or good EULAR response to the six-month anti-
TNF-a therapy and 12 (25.0%) were non-responders.
Although non-responders seem to have higher baseline
ESR, titers of RF and anti-CCP antibodies, and serum
levels of TNF-a and IL-6, when compared to respon-
ders, the differences do not reach statistical significance.
Table 1 Baseline clinical characteristics and laboratory findings in RA patients with different response to anti-TNF-a
therapy
RA with anti-TNF-a Rx. Healthy control
Moderate-good responders (n = 36) Non- responders (n = 12) (n = 12)
Mean age, years 50.4 ± 14.5 49.3 ± 10.8 47.6 ± 8.1
Female (%) 29 (80.6%) 10 (83.3%) 10 (83.3%)
Disease duration, years 5.44 ± 2.42 5.37 ± 2.37 NA
RF positivity (%) 30 (83.3%) 11 (91.6%) NA
Anti-CCP positivity (%) 29 (80.6%) 10 (83.3%) NA
ESR (mm/1
st hr) 48.9 ± 25.4 63.8 ± 24.4 NA
DAS-28 7.18 ± 0.74 7.33 ± 0.94 NA
Daily steroid dose (mg) 6.5 ± 2.1 6.9 ± 2.4 NA
TNF-a inhibitors
Etanercept (n = 14) 10 (71.4%) 4 (28.6%) NA
Adalimumab (n = 34) 26 (76.5%) 8 (23.5%) NA
Used DMARDs
Methotrexate 33 (91.7%) 11 (91.6%) NA
Sulfasalazine 31 (86.1%) 10 (83.3%) NA
Hydroxychloroqine 32 (88.9%) 10 (83.3%) NA
Ciclosporine 14 (38.9%) 5 (41.7%) NA
Data are presented as mean ± SD or number (percentage).
RA, rheumatoid arthritis; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score for 28-joints; DMARDs, disease-modifying anti-
rheumatic drugs; ESR, erythrocyte sedimentation rate; NA, not applicable; RF, rheumatoid factor; TNF-a, tumor necrosis factor-a.
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Figure 1 The comparison of circulating levels of Th17-cells and Th17-related cytokines between RA patients and HC.( A)F l o w
cytometric dot-plots of intracellular IL-17 production in Th cells obtained from peripheral blood of one representative patient with rheumatoid
arthritis and healthy control. The comparison of circulating Th17 cells frequencies is shown (B) between 48 RA patients before starting anti-TNF-
a therapy (baseline) and 12 HC. The comparison of baseline levels of serum IL-17 (C), IL-6 (D), IL-21 (E), and IL-23 (F) is shown between RA
patients and HC. The horizontal line indicates median value. P-value was assessed by Mann-Whitney U test. HC, healthy control; IL, interleukin;
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anti-TNF-a therapy is not merely a reflection of high
disease activity.
The present study is the first attempt to investigate
the effects of TNF-a inhibitors on the levels of circulat-
ing Th17 cells and Th17-related cytokines in RA
patients with a different therapeutic response. In order
to obtain a better reflection of in vivo cytokine patterns
than is achievable with PBMCs, whole blood was stimu-
lated with mitogens and lymphocytes double-stained
with IL-17 and CD4 were analysed using flow cytome-
try. Our results showed significantly higher baseline fre-
quencies of circulating Th17 cells in active RA patients
compared with healthy controls, confirming the findings
of previous studies [13,14,29]. We also showed that the
baseline levels of circulating Th17 cells were positively
correlated with DAS28 scores in RA patients. Our data
and the findings of previous studies [15,16] suggest a
potential role of Th17 cells in the pathogenesis of RA.
Similar to the results of recent studies [28], our find-
ings showed a significant decrease in the frequencies of
circulating Th17 cells after anti-TNF-a therapy, in par-
allel with the decrease in DAS28 in EULAR responders.
Although the diseases studied were different, our results
were also consistent with the findings of previous stu-
dies which showed that the TNF-a inhibitor reduced
Th17 cell responses with the amelioration of psoriatic
skin lesions [38] and that the TNFR1 inhibitor sup-
pressed the Th17 response with clinical benefits in
experimental autoimmune encephalomyelitis mice [39].
In contrast, our results showed a significant increase in
circulating Th17 cell frequencies in non-responders.
Our findings in non-responders were similar to the
results of a recent study that showed an increased fre-
quency of circulating Th17 cells after TNF-a blockade
in RA patients [29]. The divergent effects on Th17 cells
in vivo after anti-TNF-a therapy for RA patients suggest
that there may be different subsets of the immune
response to TNF-a inhibitors. It is tempting to specu-
late that the change in frequencies of circulating Th17
cells may help to differentiate between EULAR respon-
ders and non-responders because these changes occur
within the first six months of anti-TNF-a therapy.
The Th17 cells have a specific role in immune func-
tion through the production of effector cytokines.
Through the secretion of IL-17, Th17 cells act on the
differentiation of osteoclasts and bone resorption [40],
and can stimulate the monocytes to produce pro-inflam-
matory cytokines, thus amplifying the inflammatory cas-
cade [11,17,18]. In the present study, we showed that
serum IL-17 levels were significantly elevated and corre-
lated with DAS28 in active RA patients. Our data were
consistent with the results of recent studies describing
an increase in IL-17 levels in RA patients [14,41], and
they also supported the results of clinical trials showing
the therapeutic benefits of IL-17 blockade [20-22]. Dur-
ing a longitudinal follow-up of RA patients who received
anti-TNF-a therapy, we found that serum IL-17 levels
significantly decreased, in parallel with the clinical
remission in the responders, whereas increasing IL-17
levels were found in non-responders. Whether or not
this imbalance of Th17 cells and IL-17 between PB and
affected joints contributes to the change in Th17-related
cytokines after anti-TNF-a therapy remains unclear.
Accumulating evidence indicates that IL-6 can
enhance Th17 cell differentiation by promoting the
sequential engagement of IL-21/IL-23 pathways and that
it plays a critical role in Th17-dependent autoimmune
diseases [42]. In the present study, we showed that the
high baseline levels of IL-6 were positively correlated
with the frequencies of circulating Th17 cells in RA
patients. After anti-TNF-a therapy, a significant
decrease in the levels of circulating Th17 cells and IL-
Table 2 Changes in levels of Th17-cells and Th17-related
cytokines in RA patients with different therapeutic
responses
Moderate-good
responders (n = 36)
Non-responders
(n = 12)
Th17 cells (%)
Before Rx. 1.13 ± 0.16 2.94 ± 0.77#
After Rx. 0.79 ± 0.11*** 4.23 ± 0.80*
IL-17 level (pg/ml)
Before Rx 43.1 ± 7.0 92.1 ± 22.2#
After Rx 27.8 ± 3.8*** 148.6 ± 31.5*
IL-6 level (pg/ml)
Before Rx 282.9 ± 37.1 453.7 ± 120.9
After Rx 171.7 ± 22.2* 471.6 ± 124.0
IL-21 level (pg/ml)
Before Rx 1147.0 ± 216.3 863.5 ± 133.9
After Rx 769.8 ± 104.7** 942.9 ± 140.4
IL-23 level (pg/ml)
Before Rx 166.1 ± 35.1 158.4 ± 67.6
After Rx 83.3 ± 19.7*** 161.3 ± 63.3
TNF-a level (pg/ml)
Before Rx 22.0 ± 2.4 29.2 ± 7.2
After Rx 11.0 ± 1.3*** 15.2 ± 3.9**
RF titer (IU/ml)
Before Rx 116.6 ± 32.7 368.7 ± 257.9
After Rx 101.2 ± 28.2 440.0 ± 324.4
Anti-CCP titer (IU/ml)
Before Rx 58.7 ± 9.6 72.4 ± 22.0
After Rx 51.8 ± 8.7** 68.8 ± 20.3
Data are presented as mean ± SEM; RA, rheumatoid arthritis. *P < 0.05, **P <
0.005, ***P < 0.001, versus before anti-TNF-a treatment in each group
#P < 0.01, versus moderate-good responders.
Anti-CCP, anti-cyclic citrullinated peptide antibodies; IL, interleukin; RF,
rheumatoid factor; Rx, treatment; Th17, type 17 helper T cell; TNF-a, tumor
necrosis factor-a.
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IL-6 levels was observed in responders. These observa-
tions support the role of IL-6 in the differentiation of
Th17 cells [42-44], and the therapeutic benefits of IL-6
receptor inhibitors in RA patients [45].
Interleukin-21 is required to reinforce differentiation of
Th17 cells, and it plays a critical role in Th17-dependent
autoimmune diseases [46]. In contrast to IL-12, IL-23 does
not promote the development of Th1 cells, but it is crucial
for the expansion and maintenance of Th17 cells [47]. In
the present study, we showed that the baseline levels of
IL-21 and IL-23 were significantly elevated in active RA
patients, supporting their role in the pathogenesis of this
disease [42,48]. In addition, we found that serum levels of
IL-21 and IL-23 significantly decreased, in parallel with
the clinical remission in responders after anti-TNF-a ther-
apy. Consistent with our data, the results of the study by
Kageyama et al. also showed a significant decrease in
serum IL-23 levels at three and six months after anti-
TNF-a (etanercept) therapy in RA patients [27].
The mechanisms of the therapeutic effects of TNF-a
inhibitors on RA have not been fully explored. Lundy et
al. showed that TNF-a has a positive feedback effect on
Th17 cells, causing a vicious cycle of synovitis [49].
TNF-a also promotes IL-17 production by inducing
dendritic cells to direct the differentiation of Th cells
towards the Th17 phenotype [23], and by the adminis-
tration of TNF-like ligand 1A enhancing Th17 differen-
tiation with IL-17 production [50]. Our results showed a
significant decrease in the levels of circulating Th17
cells and TNF-a after effective therapy with TNF-a
inhibitors, suggesting that the down-regulation of both
Th17-related cytokines and TNF-a m a yb eo n eo ft h e
mechanisms of anti-TNF-a therapy [19]. Our findings
support the hypothesis that anti-TNF-a therapy could
reduce Th17 responsesb yb l o c k i n gt h eT N F - a-depen-
dent positive feedback system [23]. Another explanation
may be the inhibition of emigration of Th17 cells from
lymphoid organs after anti-TNF-a therapy [24].
In the present study, we showed that one-fourth of RA
patients have an inadequate response to anti-TNF-a
therapy despite a significant decrease in serum TNF-a
level, suggesting that neutralization of TNF-a cannot
fully explain the therapeutic effect of TNF-a inhibitors
in non-responders. Additionally, significantly higher
baseline levels of circulating Th17-cells and IL-17 were
observed in non-responders when compared to respon-
ders. During a longitudinal follow-up of RA patients
undergoing anti-TNF-a therapy, we found a significant
increase in circulating levels of Th17-cells and IL-17 in
non-responders. Although the cut-off value for baseline
IL-17 (40 pg/mL) used in our study was not absolute, a
multivariate logistic regression analysis showed that only
a high baseline level of IL-17 could be a significant
predictor of poor therapeutic response to TNF-a inhibi-
tors. Our observations suggest that an inadequate
response to anti-TNF-a therapy may reflect TNF-inde-
pendent but Th17-dominant inflammatory process,
which has been observed in previous studies [15,16].
This was a preliminary study that enrolled a limited
number of active RA patients who were followed up for
six months. Because we mainly investigate the effects of
anti-TNF-a therapy on Th17 cells and Th17-related
cytokines, we did not include a group of RA patients
without anti-TNF-a therapy as a disease control.
Because the patients enrolled in our study were not an
early RA population, our results might not be directly
applicable to early RA patients undergoing anti-TNF-a
therapy. Therefore, a long-term study enrolling a larger
group of patients, including an additional early RA
population, or a control group using DMARDs only, is
required to validate these findings. Although the erro-
neous increase in IL-17 levels may have been due to the
heterophilic binding by serum RF [51,52], there were no
significant differences in RF positivity or titers between
responders and non-responders in the present study.
Conclusions
Our results show that anti-TNF-a therapy not only neu-
tralizes the effects of TNF-a, but it also down-regulates
the IL-6/Th17 axis in EULAR responders. In contrast,
anti-TNF-a therapy causes a significant increase in
Th17 cells in RA patients with an inadequate response
to anti-TNF-a therapy. A high baseline level of IL-17
may have a predictive value for poor therapeutic
response to TNF-a inhibitors. Although the small sam-
p l es i z eo ft h i ss t u d yd i dn o ta l l o wf o rad e f i n i t i v ec o n -
clusion, our findings at least suggest that Th17-
dependent inflammation is implicated in the pathogen-
esis of a subset of RA patients with poor response to
TNF-a inhibitors, and that treatment targeting IL-17
may be beneficial for these patients [21,22].
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